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DNA damage response (DDR) is among the most important of the mechanisms that maintain genome stability which, when de-
stabilized, predisposes organs to cancer. Reversible phosphorylation mediated by protein kinases and protein phosphatases regu-
lates most, if not all, cellular activities, including DDR. Protein kinase inhibitors have become the main focus of targeted therapy 
and anticancer drug development. However, our limited knowledge of protein phosphatase function is compromising our capacity 
to develop therapeutic agents against phosphatases. In this review, we summarize the roles of serine/threonine protein phospha-
tases involved in DDR and propose that in situ dephosphorylation of phosphoproteins by protein phosphatases, instead of pro-
teasome-mediated degradation of phosphoproteins, is mainly employed by cells. 
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The human genome is being constantly attacked by various 
DNA damaging agents. According to the source of the toxic 
agents, DNA damage can be categorized into 2 groups, en-
dogenous (spontaneous) and exogenous (environmental) 
[1,2]. Endogenous DNA damage occurs at a high frequency 
within normal cells, mainly caused by by-products of met-
abolic and biochemical reactions, such as reactive oxygen 
species (ROS), reactive chemicals (e.g. aldehydes and S- 
adenosylmethionine). In most cases, these endogenous toxic 
agents result in the modification or hydrolysis of the base 
components of DNA, such as through oxidation, alkylation, 
deamination, depurination and depyrimidination. Mismatch 
is another kind of endogenous DNA damage occasionally 
introduced during DNA replication [3–5]. 
DNA damage caused by exogenous agents, such as ion-
izing radiation (IR) (ultraviolet (UV), X-rays, and -rays) 
and radiomimetic drugs is much more catastrophic than that 
caused by endogenous agents. UV radiation has deleterious 
effects in all living organisms, prokaryotic bacteria and eu-
karyotes, lower and higher plants, and animals including 
humans. UV radiation can be classified into 3 categories 
according to its wavelength or frequency: long wave UVA 
(315–400 nm), medium wave UVB (280–315 nm), and 
short wave UVC (100–280 nm) [6]. Most UV radiation 
(98.7%) is blocked by the Earth’s ozone layer when pene-
trating through the atmosphere, including most of UVB 
(95%) and all of UVC. Although UVA and UVB induce 
similar mutations in human skin cells [7], UVB is the pri-
mary cause of UV radiation damage, as it is directly ab-
sorbed by cellular DNA and an increasing amount reaches 
the Earth because of substantial damage to the protective 
ozone layer [6,8]. UVA causes less direct DNA damage 
because it is not absorbed by cellular DNA. Gamma rays 
and radiomimetic drugs are the most dangerous types of 
DNA damaging agents, which can cause lethal lesions, such 
as DNA double-strand breaks (DSBs), and they have been 
widely used to kill cancerous cells in cancer therapy. Ra-
diomimetic drugs, such as camptothecin (CPT) and etopo-
side are both effective anticancer drugs, which specifically 
bind and inhibit the enzyme activity of topoisomerase I and 
II respectively, which unwind DNA during replication or 
transcription [9]. Adriamycin and bleomycin interact with 
DNA by intercalation and inhibit the macromolecular bio-
synthesis [10,11]. 
 Liu B, et al.   Chinese Sci Bull   October (2011) Vol.56 No.30 3123 
1  DNA damage response 
One single cell may incur tens of thousands of DNA lesions 
daily. Fortunately, mammalian cells have developed evolu-
tionarily conserved mechanisms to cope with genotoxic 
threats, which have been termed as the DNA damage re-
sponse (DDR) (Figure 1). Upon DNA damage, cells detect 
the damaged DNA and relay the signal downstream to acti-
vate the cell cycle checkpoints to halt the cell cycle pro-
gression, allowing time for repairing the damage, or they 
tolerate the damage and continue replication, which may 
eventually cause mutations, or lead to apoptosis if the dam-
age is too severe to be repaired [12–14]. Several conserved 
repair pathways responsible for eliminating specific types of 
lesions have been identified in mammalian cells. These in-
clude direct repair, base excision repair (BER), nucleotide 
excision repair (NER), mismatch repair (MMR), homolo-
gous recombination (HR) repair, nonhomologous end join-
ing (NHEJ) repair, fanconi anemia (FA) repair and trans-
lesion DNA synthesis (TLS) [2,15–18]. There is also con-
siderable redundancy among these different pathways. A 
class of enzyme known as alkyltransferases can repair DNA 
base damage induced by alkylating agents by directly re-
moving the alkyl group. Both BER and NER repair sin-
gle-strand DNA damage. HR and NHEJ are mainly respon-
sible for DSB repair [19–21]. 
DDR involves 3 main groups of evolutionarily conserved  
 
Figure 1  A simplified schematic diagram of the DNA damage response 
(DDR). Members of the PIKK family of serine-threonine kinases ATM, 
ATR, and DNA-PKcs, and their interacting partners detect the damaged 
DNA and initiate signals to the checkpoint kinases CHK1 and CHK2. Both 
CHK1 and CHK2 phosphorylate various substrates, activating cell cycle 
checkpoints to allow time for DNA repair, fixing damaged DNA, and 
promoting apoptosis when DNA damage is too severe to be repaired. Re-
versible protein phosphorylation mediated by kinases and phosphatases 
takes part in almost every step of the DDR. 
proteins that transduce the DNA damage signals and determine 
the cell fate (Figure 1). The first group comprises the DNA 
damage sensor proteins, such as ATM (ataxia telangiectasia 
mutated protein), ATR (ataxia telangiectasia and Rad3-related 
protein), and DNA-PKcs (DNA-dependent protein kinase 
catalytic subunit), which belong to the phosphoinositide 
3-kinase-related kinase (PIKK) family. It also includes their 
physical and functional partners, including MRE11-RAD50- 
NBS1, PARP-1 (poly(adenosine diphosphate ribose) poly-
merase 1), TIP60 (60 kD Tat-interactive protein), MDC1 
(mediator of DNA damage checkpoint 1), ATRIP (ATR- 
interacting protein), Claspin, RAD17-RFC (replication fac-
tor C), Ku70/80, and Artemis. The second group comprises 
the transducer proteins, including checkpoint kinases CHK1 
and CHK2 that relay the signals to the downstream effectors, 
which are the third group [22,23] and control the cell cycle 
progression, remodeling the chromatin or repairing the 
damage [13,24,25]. The DDR pathway is a cascade of re-
versal phosphorylation events of the sensors, transducers 
and effectors. Large-scale proteomic analysis of proteins 
phosphorylated in response to DNA damage (caused by ion-
izing radiation) on consensus sites recognized by ATM and 
ATR have identified more than 900 regulated phosphoryla-
tion sites encompassing over 700 proteins, most of which 
are involved in DDR [26]. 
For example, upon DSB formation, chromatin remodel-
ing and protein and DNA modification result in dissociation 
of the sensor protein ATM, changing it from a dimer into a 
monomer and causing autophosphorylation on multiple res-
idues required for its activation [27]. The activated ATM 
phosphorylates H2AX on serine (Ser) 139, located at the 
C-terminal, to form H2AX. MDC1 directly binds to H2AX 
through its C-terminal tandem BRCT domains (the C-ter-     
minal portion of the BRCA-1 gene) [28]. At the same time, 
MDC1 facilitates the transfer of the DNA damage signal 
through ATM-dependent phosphorylation of downstream 
targets on S/T-Q residues, generating a landing platform for 
RNF8 [29,30]. Furthermore, ATM activates CHK2 by 
phosphorylation of T68, and both kinases phosphorylate 
various substrates, such as p53 and CDC25, to activate the 
cell cycle checkpoints [31,32]. 
2  Protein phosphatases 
Reversible protein phosphorylation, mediated by protein 
kinases and protein phosphatases, occurs on about one-third 
of all proteins in human cells, and controls almost every 
aspect of cellular activities, including DDR [33]. Disturbed 
protein phosphorylation has been identified in many human 
diseases, including cancer. Proteins, such as enzymes and 
receptors, are activated or inactivated by reversible phos-
phorylation, which results in a conformational change in the 
proteins structure. 
Phosphorylation occurs predominantly on serine (Ser), 
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threonine (Thr) and tyrosine (Tyr) residues, with each ac-
counting for approximately 86.4%, 11.8% and 1.8%, respec-
tively, of the human phosphoproteome [34]. In addition, 
basic amino acid residues, such as histidine, arginine or 
lysine, in prokaryotic proteins can also be modified via 
phosphorylation [35]. The human genome encodes 518 
protein kinases, 428 of which phosphorylate Ser or Thr res-
idues, and the remaining 90 kinases belong to the Tyr ki-
nase family [36–38]. By contrast, there are only about 147 
protein phosphatase catalytic subunits identified in the hu-
man genome, with 107 serving as Thr phosphatases or du-
al-specificity phosphatases [38]. Surprisingly, the human 
genome only encodes 40 Ser/Thr phosphatases, whereas 
more than 98% of the phosphorylation occurs on Ser/Thr 
residues. 
Phosphatases can be classified into 3 groups according to 
their sequence identity, structure, substrate specificity and 
catalytic mechanisms, namely Ser/Thr protein phosphatases, 
Tyr protein phophatases, dual specificity protein phospha-
tases, and the FCP/SCP/HAD family. The FCP/SCP/HAD 
family uses an Asp-based catalysis mechanism with a 
DXDXT/V catalytic motif in which the first aspartate serves 
as a phosphoryl acceptor during the substrate dephosphory-
lation [39]. 
Ser/Thr protein phosphatases comprise the PPP (phos-
phoprotein phosphatase) family and the PPM (protein 
phosphatase, Mg2+ or Mn2+ dependent family, also PP2C 
family) family and are responsible for dephosphorylation of 
phosphoserines or phosphothreonines [40]. The catalytic 
subunit of the PPP family members itself does not have any 
enzymatic activity. It forms heterodimeric or heterotrimeric 
holoenzymatic complexes with regulatory/scaffolding sub-
units. These holoenzymes thus gain catalytic activity, spe-
cific subcellular localization, and specific substrate recogni-
tion. The PPP family is further divided into 3 subfamilies: 
PP1, PP2A and PP2B. PP4 and PP6 are closely related to 
PP2A, while PP7 was grouped into the PP2B subfamily 
because of its requirement for Ca2+ [41]. Most members of 
this family have roles in DDR [42]. The PPM members are 
catalytically Mg2+ or Mn2+ dependent, sharing structural 
similarity, however, there is no sequence homology with the 
PPP members at their active sites. The human genome en-
codes 18 PPM members [43]. The catalytic subunits of this 
family exhibit enzymatic activity without the requirement of 
additional regulatory subunits, however, their interacting 
partners may play a role in determining their subcellular 
localization and modulate their enzymatic activity. PPM1D 
or WIP1 (wild type p53-inducible phosphatase 1) is a sig-
nificant member of this family involved in DDR (Table 1). 
To date, 107 protein Tyr phosphatases (PTPs) have been 
identified in the human genome, 106 of which have mouse 
orthologs, and only 81 of these are catalytically active. 
Compared with about 90 catalytically active Tyr kinases, it 
is reasonable to assume that the PTPs have comparable sub-
strate specificities. PTPs have been found to play critical 
roles in human diseases, such as diabetes, Sézary syndrome, 
and Noonan syndrome, and at least 30 PTPs have been im-
plicated in tumor growth [38]. PTPs are becoming a prom-
ising drug target in drug development [44]. 
We will summarize Ser/Thr protein phosphatases in-
volved in DDR (Table 1) in the following sections. 
2.1  PP1 
Protein phosphatase 1 (PP1) is widely expressed in mam-
malian cells. It includes 3 highly-related isoforms, PP1, 
PP1, and PP1, encoded by separated genes [45]. These 
isoforms have more than 89% identity in amino acid se-
quence. PP1 has two alternative splicing variants, PP11 
and PP12 [46]. Localization patterns of PP1 isoforms are 
dynamic in a cell cycle-dependent manner. PP1 localizes 
to the nucleus during the interphase, while PP1 and PP1 
additionally accumulate in the nucleoli [47,48]. PP1 has 
been reported to interact with various subunits through its N 
terminus. Sequence analysis of all the interacting partners 
has revealed that most of these proteins contain a consensus 
PP1-binding motif: (R/K)×1(V/I)×2(F/W), where ×1 may 
be absent or any residue apart from the large hydrophobic 
residues, and ×2 denotes any amino acid except large hy-
drophobic residues, phosphoserine and probably aspartic  
Table 1  Ser/Thr protein phosphatases and their substrates in DDR 
Sub-family Phosphatases Catalytic subunits Regulatory subunits Involved in DDR Identified substrates in DDR 
PPP PP1 , , 1, 2 >90 yes CDC25, CHK1, BRCA1, p53,  
KAP1, etc. 
 




PP4 PPP4C PP4R1, PP4R2, PP4R3,  
PP4R3, PP4R4 
yes H2AX, RPA2 
 
PP6 PPP6C PP6R1, PP6R2, PP6R3 yes H2AX 
 
PP2B(PP3) PPP3CA, PPP3CB, PPP3CC  unknown 
 
PP5 PP5  yes  
 
PP7 PP7  unknown  
PPM/PP2C PPM1A, B, etc.  
(18 members) 
PPM1A, B, etc.  PPM1D ATM, ATR, CHK1, CHK2,  
p53, H2AX, etc. 
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acid [49,50]. More than 180 conserved mammalian proteins 
have been identified as potential binding partners of PP1. 
PP1 exists in as many as 650 distinct complexes, which may 
contribute to its subcellular localizations, substrates speci-
ficity, and account for the roles of PP1 in the regulation of 
an enormous variety of cellular functions [50,51]. One pre-
requisite for activation of PP1 is the removal of the inhibi-
tory phosphothreonine residue at the PP1 C-terminus, which 
is phosphorylated by cyclin-dependent kinases (CDKs) in a 
cell cycle-dependent manner [52]. 
The roles of PP1 in DDR have been reported in both 
DNA damage signaling and DNA repair. Upon DNA dam-
age, PP1 is activated after ionizing radiation by removing 
the inhibitory phosphorylation sites in an ATM dependent 
manner [53]. PP1 also regulates the ATM activation by its 
chromatin-targeting subunit, Repo-Man [54]. Studies in 
Xenopus egg extracts demonstrate that Repo-Man interacts 
with ATM and PP1 through distinct domains, leading to 
PP1-dependent regulation of ATM phosphorylation and 
activation. Overexpression of the wild-type Repo-Man, but 
not the PP1-binding deficient mutant, attenuates the DNA 
damage-induced ATM activation [53,55,56]. The mecha-
nisms underlying PP1 participation in DNA damage during 
interphase and mitosis have been elucidated by identifica-
tion of several other PP1 substrates, such as CDC25, CHK1, 
BRCA1 and p53 [57–62]. CDC25, a crucial regulator of the 
G2/M transition, is a highly conserved dual-specific phos-
phatase and a key target of the checkpoint machinery that 
ensures genetic stability. 
Dis2, the Schizosaccharomyces pombe homolog of PP1, 
is required for dephosphorylation and deactivation of CHK1 
and recovery from DNA damage-induced G2 checkpoint 
arrest [59,60]. BRCA1 is also identified as a PP1 substrate 
during DNA damage recovery [61,63]. PP1 interacts with 
BRCA1 via its PP1-binding motif (898KVTF901) and me-
diates dephosphorylation of BRCA1 at several sites, which 
were previously phosphorylated by ATM, ATR, or CHK2 
upon DNA damage. Mutation in the PP1-binding motif in 
BRCA1 impaired the DNA damage-induced Rad51 foci 
formation, and compromised its function in the HR [55,61, 
63]. Moreover, low levels of BRCA1 may be related to the 
variable levels of PP1 and  in primary sporadic human 
breast tumors, indicating an important role of PP1 during 
the development of breast cancer, and may result from an 
aberration in its phosphorylation status [62]. p53 is another 
substrate of PP1. As a multifunction factor, the roles and 
phosphorylation status of p53 have been well established 
during the past decades [64]. Upon DNA stress, such as 
-irradiation or UV irradiation, p53 is phosphorylated at  
Ser15 and Ser20 by ATM/CHK2 and ATR/CHK1 [65–68]. 
PP1 dephosphorylates UV-induced p53 phosphorylation at 
Ser15, and this can be disturbed by okadaic acid (OA) and 
GADD34 (growth arrest and DNA damage 34). GADD34, 
one of the PP1 binding partners, inhibits PP1 binding with 
p53, interfers with the dephosphorylation of p53 and sus-
tains the amount of phospho-p53 after UV-treatment [69]. 
New data suggest that PP1 may be involved in the regula-
tion of cross talk between different post-translational modi-
fications in DDR, e.g., KAP1 (Krüppel-associated box as-
sociated protein 1) phosphorylation and sumoylation. KAP1 
provides a prosurvival advantage by contributing to tran-
scriptional repression of the DNA damage response genes 
p21, Bax, noxa and Puma. KAP1 phosphorylation antago-
nizes its sumoylation and keeps it inactive. PP1 is essen-
tial to establish the minimal level of Ser-824 phosphoryla-
tion required for KAP1’s corepressor function in unstressed 
cells. By contrast, PP1β is recruited to KAP1 post 
Dox-treatment, and its stimulatory effect on sumoylation is 
expanded from KAP1 to RanGAP1. These findings provide 
novel mechanistic insights into how PP1 impacts DDR, 
influencing not only KAP1 Ser-824 dephosphorylation, but 
also its sumoylation and targeted gene expression [2]. 
2.2  PP2A 
PP2A is a major Ser/Thr phosphatase with distinct roles in 
regulation of cell cycle progression, cell growth and devel-
opment, cytoskeleton dynamics, and cell mobility [70]. Two 
isoforms of PP2A are encoded by 2 distinct and unlinked 
genes, PP2ACα and PP2ACβ. These 2 isoforms share 97% 
identity in primary amino acid sequences, there is no anti-
body available to date that can distinguish them [70]. They 
are expressed in all tissues and cell types and distributed in 
the cytosol, nucleus, and chromatins. Knockout of Ppp2c in 
mice leads to death at embryonic day 5.5. It has been as-
sumed that they are functionally redundant. However, it would 
be interesting to see the phenotypes of Ppp2c knockout mice 
and if these two isoforms can rescue each other in vivo [71]. 
Active forms of PP2A exist as heterotrimeric complexes, 
each of which consists of a catalytic subunit C, a structural 
subunit A and a regulatory subunit B [70]. The structural 
subunit A interacts with the catalytic C subunit by its car-
boxyl terminus, and forms a horseshoe-shaped scaffold. 
There are two A isoforms encoded by two alternative genes, 
PR65 and PR65, with 87% similarity in their primary 
amino acid sequences [72]. The heterodimer AC remains 
inactive without the addition of the regulatory B subunits. 
To date, 15 genes have been identified in the human ge-
nome. These genes encode at least 26 different alternatively 
spliced variants representing the B subunits of the PP2A 
holoenzyme. These B subunits have been divided into 4 
families based on sequence homology, namely, B (B55 or 
PR55), B′ (B56 or PR61), B″(PR48/59/72/130), and B′″ 
(PR93/110) families. It is believed that PP2A achieves reg-
ulatory flexibility and substrate specificity via the specific 
association of the core dimer with one of the regulatory B 
subunits [73]. 
Involvement of PP2A in DNA damage signaling, DNA 
repair and apoptosis has been established. Upon DNA 
damage, PP2A is activated, partially regulated by methyla-
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tion on the catalytic domain [74]. PP2A regulates the DNA 
damage-induced G1/S checkpoint, and several checkpoint 
proteins, including Rb (retinoblastoma), p107, and p53, 
which are PP2A substrates [70,75]. UV-induced dephosphor-
ylation of Rb and p107 by PP2A facilitates their interaction 
with E2F to arrest cells in the G1 phase, inhibiting cell pro-
liferation. Furthermore, PP2A participates in the net accu-
mulation of un(der)-phosphorylated Rb in the soluble frac-
tion following DNA damage in the S phase. PP2A dephos-      
phorylates p53 at Ser37 and Thr55 [76]. Dephosphorylation 
of p53 Ser37 downregulates transcriptional activity of p53 
in response to DNA damage. Thr55 dephosphorylation sta-
bilizes p53 in response to DNA damage, and a prerequisite 
of this process is the ATM-dependent phosphorylation of 
p53 at Ser15, which enhances the interaction between PP2A 
regulatory subunit B56(),(p53) [77]. 
PP2A has an essential role in the activation of the IR- 
induced G2/M checkpoint. Expression of the oncogenic in-
hibitor of the PP2A catalytic subunits and HOX11 in T-cell 
lines stops the G2 arrest induced by  irradiation. Further-
more, inhibition of PP2A by inhibitors or siRNA abrogates 
the IR-induced activation of ATR and CHK1, as well as 
phosphorylation of Cdc2-Tyr15, and attenuates the IR-in-     
duced G2/M arrest [78]. Similarly, expression of an N-ter-     
minally truncated form of the B56 subunit in 3T3 cells also 
abrogates radiation-induced G2 arrest. PP2A might also be 
involved in the deactivation of PLK1 by dephosphorylation 
upon mitotic DNA damage [79]. PP2A/B56 is also in-
volved in the regulation of the activity of CDC25 at the 
G2/M transition and recovery from DNA damage, by 
dephosphorylating Cdc25 at a site (T138) whose phosphor-
ylation is required for 14-3-3 release [80]. 
Various checkpoint signaling factors are substrates of 
PP2A. For example, PP2A may dephosphorylate DNA-PK 
protein kinase and thus regulate its kinase activity [81]. 
Phosphorylation-induced inhibition of the DNA-PK kinase 
activity is restored by the addition of a purified PP1 or 
PP2A catalytic subunit, and this reactivation is obstructed 
by microcystin, a protein phosphatase inhibitor [81]. PP2A 
counteracts ATM- and ATR-mediated DNA damage check-    
points in Xenopus egg extracts independent of Cdk2- and 
Cdc7-mediated checkpoints, and it is required for the acti-
vation of the ATR-CHK1 pathway in response to Vpr (viral 
protein R) [81,82]. Upon IR-induced DSBs or other DNA 
lesions, CHK2 is phosphorylated at Thr68 and activated in 
an ATM-dependent manner, then it phosphorylates various 
downstream proteins, including B subunits of PP2A, in-
creasing its phosphatase activity [82]. PP2A in turn interacts 
with and dephosphorylates Thr68-CHK2 to turn off the 
DNA damage signal when the damage has been repaired, 
forming a negative regulation feedback loop. 
2.3  PP4 
PP4 is closely related to PP2A, exhibiting phosphatase ac-
tivity in a heterodimeric or heterotrimeric holoenzyme [83, 
84]. PP4 has been known to be a ubiquitous Ser/Thr phos-
phatase in several species for more than a decade. Mamma-
lian PP4c share 65% amino acid identity with PP2c and 
PP2c. Five regulatory subunits have been identified, PP4R1, 
PP4R2, PP4R3, PP4R3 and PP4R4, forming 4 potential 
holoenzymatic complexes, PP4c-PP4R1, PP4c-PP4R4, PP4c- 
PP4R2-PP4R3, and P4c-PP4R2-PP4R3 [83,84]. PP4 has 
roles in several cellular processes, including organelle assem-
bly, centrosome maturation, spliceosome assembly, regulation 
of histone acetylation and chromatin remodeling [85–87]. 
Its roles in DDR have been appreciated recently. Gingras 
and colleagues identified several novel, evolutionarily con-
served PP4C-containing complexes involved in cisplatin 
sensitivity [88]. Deletion of any of the PP4 subunit orthologs 
in Saccharomyces cerevisiae elicited cisplatin hypersensi-
tivity [89]. Furthermore, human PP4R3 complemented yeast 
psy2 deletion, and Drosophila melanogaster lacking func-
tional PP4R3 (falafel) exhibited cisplatin hypersensitivity, 
suggesting a highly conserved role for PP4 in DNA damage 
repair. Finally, PP4R3 was found to, at least in part, target 
PP4c to the DNA damage repair machinery via an interac-
tion with Rad53 (hCHK2) [42,88,90]. Investigations in bud-
ding yeasts demonstrated that phosphatase Pph3-containing 
complex facilitated DNA damage checkpoint recovery by 
regulating the phosphorylation status of H2A. In addition, 
Pph3 forms a complex with PsyII (Pph3-PsyII) that specifi-
cally binds and dephosphorylates Rad53 during replication 
stress recovery, this is required to restart stalled replication 
forks [84,91]. 
Studies in mammalian cells have revealed that PP4C, 
PP4R2, and PP4R3 holoenzymatic complexes specifically 
dephosphorylate ATR-mediated H2AX generated during 
DNA replication [83,92]. The PP4C-PP4R2 complex regu-
lated the RPA2 phosphorylation level to regulate in turn the 
HR repair [93]. Overexpression of PP4 has been found in 
human breast tumors and lung tumors, and inhibition of its 
expression sensitizes cancer cells to cisplatin treatment [94]. 
Overexpression of PP4 and other protein phosphatases in 
tumors may confer resistance to chemotherapeutic drug-in-     
duced DNA damage because DNA damage-induced H2AX 
may be dephosphorylated regardless of repair. This would 
allow cancer cells to continue proliferating in the presence 
of damaged DNA. These studies have established that PP4 
is involved in DDR and could be a target for drug develop-
ment and cancer therapy. 
2.4  PP6 
PP6 is the mammalian homolog of yeast Sit4, which is 
highly related in sequence to the PP2A-like Ser/Thr phos-
phatases. Phenotypes induced by inhibition of Sit4 could be 
rescued by ectopic expression of mammalian PP6 [95]. The 
phosphatase activity of Sit4 depends on its interacting part-
ners, Sit4-associated proteins (SAP) [96]. Three regulatory 
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subunits containing SAP domains, which were renamed as 
PP6R1, PP6R2 and PP6R3, respectively, have been identi-
fied in mammals and shown to coprecipitate with PP6c, but 
not with PP4 or PP2A [97,98]. All three SAP subunits can 
individually associate with PP6c, but exhibit nonoverlap-
ping substrate specificities. DNA-PK interacts with PP6C, 
and its regulatory subunits PP6R1, PP6R2 and PP6R3. Si-
lencing of PP6 leads to sensitivity to IR and delays release 
from the G2/M checkpoint [99]. Furthermore, silencing of 
PP6c or PP6R1 resulted in sustained phosphorylation of 
H2AX after IR, while neither of the phosphorylation states 
of DNA-PK or ATM was compromised [99]. This demon-
strated that neither DNA-PK nor ATM is a substrate of 
PP6c, DNA-PK may instead recruit PP6 to sites of DNA 
damage to dephosphorylate H2AX, remove IR-induced 
foci, and release from the G2/M checkpoint in vivo [99]. 
This appears contradictory to the findings of other reports 
[99–101], in which inhibition of PP6c or PP6R1 expression 
by siRNA impairs DNA-PK activation in response to IR, 
though all reports demonstrated that preventing PP6c ex-
pression sensitizes tumor cells to IR. Our laboratory further 
demonstrated that depletion of PP6c or PP6R2, but not 
PP6R1, compromised repair of CPT-induced DSBs or 
I-SceI-induced DSB, suggesting that DNA lesions induced 
by different agents may require different PP6 holoenzymes 
[102]. 
Our laboratory also examined expression status of PP6c 
and its regulatory subunits in breast tumor samples derived 
from a cohort of approximately 200 breast cancer patients 
[102]. It was unexpected to find that expression of PP6c, 
PP6R2, and PP6R3 was lowered in breast cancer samples in 
comparison with benign breast lesions, suggesting that PP6 
may have a protective role during breast tumorigenesis. 
2.5  PP5 
PP5 is a unique phosphatase of the PPP family, not only in 
terms of its structure, but also its phosphatase activity. PP5 
has a peptidyl-prolyl cis-trans-isomerase-like (PPIase-like) 
domain and 3 consecutive tetratricopeptide repeat (TPR) 
domains responsible for protein interaction, neither of 
which have been identified in other protein phosphatases 
[103]. Its phosphatase domain resides in the C-terminus and 
shares about 48% sequence similarity to other phosphatases, 
such as PP1, PP2A and PP2B. PP5 exhibits low phospha-
tase activity under normal conditions, which may be a con-
sequence of the inhibitory interaction between its C-termi-     
nus region (responsible for the phosphatase activity) and its 
N-terminus TPR region [103]. PP5 plays roles in prolifera-
tion, migration, differentiation, electrolyte balance, apopto-
sis, survival, and also DDR [103,104]. PP5 is required for 
the activation of both ATM-mediated and ATR-mediated 
DNA damage checkpoints through enhanced direct interac-
tion in response to genotoxic stresses [105–107]. PP5 inter-
acts with ATM depending on DNA damage, and inhibition 
of PP5 expression attenuated ATM activation. The mouse 
model lacking PP5 does not arrest the ATM-mediated cell 
cycle [108]. PP5 is also required for the activation of ATR 
and phosphorylation of Rad17 and CHK1 after UV or hy-
droxyurea treatment [107]. While no phosphorylation resi-
dues have been identified that can be reversed by PP5, the 
available data suggest that PP5 may regulate the phosphor-
ylation status of 53BP1 in response to radiomimetic agents, 
such as neocarzinostatin (NCS) [109]. Overexpression of 
PP5 was found in human breast cancer, indicating that ele-
vated PP5 protein levels may promote tumor progression 
[110]. 
2.6  PPM1D 
PPM1D/WIP1 was originally identified as a wild-type p53 
induced protein phosphatase in response to IR [111]. Sub-
sequent studies have revealed that a wide range of damage 
agents, such as UV, anisomycin, H2O2 and MMS (methyl 
methanesulfonate) also induced its expression [111,112]. It 
is a monomeric Ser/Thr phosphatase with monogenic activ-
ity. Its phosphatase activity requires the presence of Mg2+ or 
Mn2+, and it is relatively insensitive to OA treatment [113]. 
Overexpression of PPM1D has been reported in multiple 
human cancers, including neuroblastomas, pancreatic ade-
nocarcinomas, and medulloblastomas, as well as ovarian 
and gastric carcinomas [114–117]. Its oncogenic properties 
have been elucidated in several tumor suppressor pathways 
[118]. Overexpression of PPM1D in cells removes the IR- 
or UV-induced intra-S and G2-M cell cycle checkpoints, 
whereas repression of PPM1D expression prolongs these 
checkpoints [119,120]. Identification of its substrates, 
which share a p(S/T)Q motif, has also revealed the critical 
function of PPM1D as a regulator of DDR [113,121]. Upon 
UV-irradiation, p53 is phosphorylated by the stress-respon-    
sive kinase p38 mitogen-activated protein kinase, at Ser33 
and Ser46, which enhances the activity of p53 and ulti-
mately results in cell cycle arrest or apoptosis [122]. The 
activated p53 then induces the expression of PPM1D, which 
in turn attenuates the phosphorylation of p53 as well as the 
conserved active site of p38, to suppress its transcriptional 
activity and UV-induced apoptosis. Furthermore, PPM1D 
facilitates inactivation of the BER by dephosphorylating 
and deactivating the crucial regulator UNG2, which is a 
nuclear isoform of uracil-DNA glycosylase activated upon 
UV damage [123]. Thus, p-38 MAPK-p53-PPM1D forms a 
negative feedback loop in the UV-induced DNA damage 
response. The ATR-CHK1-p53 pathway also occurs upon 
UV-induced DDR. Upon UV damage, ATR phosphorylates 
and activates CHK1 at Ser345, as well as p53 at Ser15. At 
the same time, the activated CHK1 also phosphorylates p53 
at Ser20 to stop the interaction between p53 and MDM2, 
which is an E3 ligase and expressed in a p53 dependent 
manner, thus stabilizing p53 after DNA damage [124]. In 
response to DSBs, ATM turns into an active form via auto-
3128 Liu B, et al.   Chinese Sci Bull   October (2011) Vol.56 No.30 
phosphorylation and monomerization [125], and then phos-
phorylates multiple downstream effectors, including CHK2- 
T68, p53-Ser15 [125,126]. The activated CHK2 phosphor-
ylates p53-Ser20 and MDM2, leading to the stabilization of 
p53 [127]. Activated p53 induces the expression of PPM1D, 
which in turn dephosphorylates and inactivates the upstream 
proteins, ultimately diminishing the DNA damage signal 
[121]. H2AX is another new substrate reported to be 
dephosphorylated by PPM1D during checkpoint recovery, 
and the activity of PPM1D must be tightly regulated to en-
sure proper damage repair [128,129]. These studies indicate 
that PPM1D is an important negative regulator of DDR. 
3  Phosphatases for γH2AX 
H2AX is rapidly phosphorylated by ATM/ATR/DNA-PK 
on Ser139 (H2AX) surrounding sites of DNA damage 
[130], which serve as a platform for recruitment and en-
richment of DDR factors [131,132]. H2AX is a marker for 
DSBs. It has been puzzling when and how H2AX is re-
moved. Thus far, several protein phosphatases have been 
reported to dephosphorylate H2AX, these include PP2A, 
PP4C, PP6C, PPM1D and PPM1G [83,92,99,128,133,134]. 
We and our collaborators have shown that PP4C forms 
complexes with PP4R2, and PP4R3, and specifically depho-   
sphorylates ATR-mediated H2AX within the mono-nucle-     
osomes generated during DNA replication. PP2A is mainly 
responsible for H2AX in response to exogenous DNA 
damage [83]. We and our collaborators have also revealed 
that H2AX is dephosphorylated by PP6 both in vitro and in 
vivo [99,102]. Silencing of either PP6c or PP6R1 led to 
sustained H2AX levels after IR, whereas inhibition of 
PP6c or PP6R2 expression, but not PP6R1 expression, re-
sulted in sustained H2AX levels after CPT treatment [102]. 
It is very interesting that H2AX generated under different 
circumstances is dephosphorylated by different phosphatas-
es, and if by the same phosphatase, the requirement of reg-
ulatory/scaffolding subunits is different. These studies con-
firm that different regulatory/scaffolding subunits may be a 
key determinant of phosphatase-substrate specificity. 
4  Perspective 
OA-mediated inhibition effects have been attributed to 
PP2A phosphatase. In fact, OA also blocks phosphatase 
activity of PP4 and PP6. Therefore, it is necessary to 
re-examine if PP4 or PP6 participates in or regulates these 
“assumed” PP2A-mediated cellular activities reported in the 
literature. 
Proteasome-mediated degradation of phosphoproteins 
has been validated in a significant number of phospho-targets, 
however, degradation and protein resynthesis are extremely 
costly in terms of adenosine triphosphate consumption. Given 
the smartness of both normal cells and cancer cells, the ad-
vantage of using this costly approach to deactivate a phos-
phoprotein is not clear. Though protein phosphatemediated 
in situ dephosphorylation of phosphoproteins has been only 
identified to date in significantly fewer phospho- targets, we 
hypothesize that in situ dephosphorylation by protein phos-
phatases is a major pathway that deactivates phosphopro-
teins. 
One third of eukaryotic proteins are phosphorylated and 
more than 98% of phosphorylation events occur on Ser/Thr 
residues. The human genome only encodes about 140 cata-
lytic subunits of protein phosphatases, about 40 of which 
are Ser/Thr phosphatases. Therefore, it would be very deli-
cate and complex for a phosphatase to exhibit its specificity 
for substrate recognition and recruitment. As discussed 
above, complex formation of a holoenzyme plays an im-
portant role in determining its substrate specificity. It is a 
challenging and important task to determine physiological 
substrates and their corresponding specific holo-phospha-     
tases in the near future. 
Reversible protein phosphorylation plays a critical role in 
tumorigenesis. Protein kinases have become the second 
most important target in the development of anticancer 
drugs, and it is logical to expect that protein phosphatases 
are also potential anticancer drug targets. Indeed, a number 
of natural compounds have been identified to target the cat-
alytic subunit and block its phosphatase activity, however, 
these compounds have either not been tested in a clinical 
trial or they failed in the early stage of a trial because of 
their side effects. These side effects result from the fact that 
a phosphatase catalytic subunit may have many targets in-
volved in many molecular pathways. To achieve pathway- 
or substrate-specific blockage, rational design of small 
molecules targeting the catalytic-substrate interaction or the 
regulatory subunit-substrate interaction is important. 
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